Karen Midthun
Biographic Data
| ID | 6061056 |
|---|---|
| NAME | Karen Midthun |
| GIVEN NAMES | Karen |
| FAMILY NAME | Midthun |
| SIGNATURE | MIDTHUN K |
| AFFILIATIONS | At the time this article was written, Susan S. Ellenberg was with the Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Md. Mary A. Foulkes, Karen Midthun, and Karen L. Goldenthal are with the Center for Biologics Evaluation and Research, US Food and Drug Administration. |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 2 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2004 |
| LATEST PUBLICATION YEAR | 2005 |
| H-INDEX | 1 |
Evaluating the Safety of New Vaccines
Public concerns about the safety of vaccines arise on a regular basis. In November 2000, a workshop titled “Evaluation of New Vaccines: How Much Safety Data?” was convened by US Public Health Service agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, to discuss appropriate methods for evaluating the safety of…
Getting the Science Right and Doing the Right Science in Vaccine Safety
Because of the potential for conflicts of interest, Salmon et al. propose in this issue the creation of an independent vaccine safety board to assume responsibility for assessing the safety of licensed vaccines. We believe that the current system at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) facilitates needed interactions between those involved in risk assessment and risk management, provides …
Evaluating the Safety of New Vaccines
Public concerns about the safety of vaccines arise on a regular basis. In November 2000, a workshop titled “Evaluation of New Vaccines: How Much Safety Data?” was convened by US Public Health Service agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, to discuss appropriate methods for evaluating the safety of…
Getting the Science Right and Doing the Right Science in Vaccine Safety
Because of the potential for conflicts of interest, Salmon et al. propose in this issue the creation of an independent vaccine safety board to assume responsibility for assessing the safety of licensed vaccines. We believe that the current system at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) facilitates needed interactions between those involved in risk assessment and risk management, provides …
Evaluating the Safety of New Vaccines
Public concerns about the safety of vaccines arise on a regular basis. In November 2000, a workshop titled “Evaluation of New Vaccines: How Much Safety Data?” was convened by US Public Health Service agencies, including the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration, to discuss appropriate methods for evaluating the safety of…
Administration (probate law) (1 works) · Advisory committee (1 works) · Disease control (1 works) · Environmental health (1 works) · Family medicine (1 works) · Food and drug administration (1 works) · Immunization (1 works) · Immunology (1 works) · Immunology (1 works) · Influenza Virus Research Studies (1 works)